Apheresis Equipment Market Size, Share, Growth, and Industry Analysis, By Type (Centrifugation Apheresis Equipment,Membrane Apheresis Equipment), By Application (RBC,Platelets,Plasma), Regional Insights and Forecast to 2035

Apheresis Equipment Market Overview

Global Apheresis Equipment Market valued at USD 2725.63 Million in 2026, projected to reach USD 7440.24 Million by 2035, growing at a CAGR of 11.8%.

The global Apheresis Equipment Market featured approximately 2 898.9 million USD in device kit spend during 2023 and accounted for 35.0 percent of global market value in North America in that year. Disposable apheresis kits contributed roughly 2 092.2 million USD in 2023 within global product segmentation. The neurology therapeutic segment held around 50.94 percent of application share in 2023, while plasmapheresis procedures made up about 51.98 percent of procedures in 2023. In hematology, approximately 70 000–100 000 U.S. patients suffer Sickle Cell Disease, generating device utilization. Plasma exchange platforms numbered in thousands of units globally by mid‑2024. These figures underscore market scale and medical reliance on Apheresis Equipment Market technologies.

The U.S. Apheresis Equipment Market registered around 917.9 million USD in 2023 with disposable kits dominating product share. In 2023 approximately 184 720 new cases of leukemia, lymphoma, and myeloma were diagnosed in the U.S., representing around 9.4 percent of total cancer cases. American Red Cross collects an estimated 6.8 million blood donations annually. Hemophilia A affects nearly 1 in 5 000 male newborns, while approximately 37 million U.S. adults (15 percent) have chronic renal disease. Around 29 000 red‑blood‑cell units are needed daily in U.S. healthcare. These figures point to a robust U.S. Apheresis Equipment Market Report demand environment.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: 70 percent of therapeutic procedures by neurology share; neurology segment 50.94 percent application share.
• Major Market Restraint: 1 percent of global AML cases among all cancers; limitation on procedure outcomes in HTG‑AP (plasmapheresis showing no improved organ failure).
• Emerging Trends: AI integration improving process accuracy by processing real‑time data across thousands of procedures.
• Regional Leadership: North America held 36 percent geographic share in 2023.
• Competitive Landscape: Top players account for 38 percent dialysis market share in U.S.; Haemonetics revenue USD 1.31 billion (FY 2024).
• Market Segmentation: Plasmapheresis procedures 51.98 percent procedure share; disposable kits 72 percent of product revenues (2 092.2 million USD of 2 898.9 million USD).
• Recent Development: Asahi Kasei Medical acquired Bionova in June 2022; U.S. market size 1.01 billion USD in 2024.

Apheresis Equipment Market Latest Trends

The Apheresis Equipment Market Report highlights widespread AI adoption, with processing algorithms optimizing separation precision across thousands of procedures annually. In 2024 the U.S. segment alone reached 1.01 billion USD in size, supporting ongoing trend momentum in AI‑enabled equipment development. AI tools reduced manual logging time by 20 percent in pilot studies across leading centers. Disposable apheresis kits continued to account for approximately 72 percent of global product units in 2023, representing 2 092.2 million USD of a total 2 898.9 million USD market spend. Neurology procedures maintained 50.94 percent application share, especially therapeutic plasma exchange to manage 2.8 million global multiple sclerosis cases. Plasmapheresis procedures comprised 51.98 percent of procedures in 2023, with 184 720 hematologic malignancy cases diagnosed in U.S. prompting procedure utilization. North America sustained 36 percent share of global volume, and Asia‑Pacific reached several hundred million USD in equipment deployment in 2023. Blood donation volumes in U.S. alone reached 6.8 million units annually, supporting donor‑based equipment demand. These concrete numerical facts reinforce clear Apheresis Equipment Market Trends for B2B stakeholders.

Apheresis Equipment Market Dynamics

DRIVER

"Rising demand for blood components"

The increasing prevalence of chronic renal disease affecting 37 million U.S. adults (15 percent) and hemophilia A incidence (1 in 5 000 male births) creates sustained need for red cell and platelet apheresis units. U.S. demand reaches 29 000 red‑cell units daily. Neurology segment holds 50.94 percent application share driven by 2.8 million MS patients and 1 in 100 000 annual GBS cases. Therapeutic apheresis for hematology addresses 70 000‑100 000 U.S. sickle cell disease patients. These figures underscore why rising disease burden fuels adoption of apheresis technology in clinical protocols across thousands of hospitals.

RESTRAINT

"Procedure inefficacy in specific patient segments"

Plasmapheresis for HTG‑induced acute pancreatitis lacks demonstrable outcome improvement in organ failure duration, limiting operator adoption. Acute Myeloid Leukemia (AML) comprises 20 800 new U.S. cases and 11 220 deaths in 2024; leukapheresis uptake remains limited due to marginal survival benefit. The 1 percent overall cancer case share by AML reduces capital justification for specialty platforms. These numeric procedure outcome limitations inhibit broader procedure-based investment decisions at healthcare facilities.

OPPORTUNITY

"AI and cell therapy integration"

Terumo BCT launched a cell‑therapy training program in May 2023 to train manufacturers in cell collection processes across hundreds of operations. AI-enabled equipment improves accuracy, increases throughput, and reduces operator error by 20 percent in trials. Asia‑Pacific nations such as Japan, China and India saw equipment deployment rising hundreds of millions USD in 2023, aligned with increased geriatric population and greater disease prevalence. With blood component demand and plasma donation volumes exceeding millions annually in U.S. and Canada, companies can tap into scalable markets through technology-led expansion.

CHALLENGE

"Skilled professional shortages and safety constraints"

Lack of skilled operators limits deployment of sophisticated apheresis units across smaller centers. Blood contamination risks remain, creating need for strict quality protocols and limiting volume growth. Equipment costs (capital plus disposable kit spend) present budgeting challenges at hundreds of thousands USD per unit plus thousands USD per kit use. These numeric constraints deter broad uptake in emerging regions and non‑tertiary care settings.

Apheresis Equipment Market Segmentation

Segmentation by type and application reflects usage intensity. In component segmentation, red blood cell (RBC) apheresis supports Sickle Cell Disease affecting 70 000‑100 000 U.S. patients; plateletpheresis addresses trauma and liver disease, with 29 000 RBC units daily plus rising platelet demand. Plasma (plasmapheresis) accounted for 51.98 percent procedure share. By application, centrifugation apheresis methods dominate, representing majority of apheresis units sold (devices segment fastest growth), while membrane apheresis adoption is rising. Centrifugation-based platforms accounted for the majority of MDR‑approved units in 2023, whereas membrane-based separation units increased by 15 percent volume year‑on‑year across key US hospitals.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

RBC Apheresis (erythrocyte exchange): Approximately 70 000–100 000 U.S. patients with SCD use RBC apheresis annually; RBC apheresis accounts for significant share of therapeutic procedures in hematology. U.S. red cell demand reaches 29 000 units daily, supporting consistent RBC collector unit utilization. RBC-centric platforms are installed in over 500 hospitals across major markets. The RBC apheresis segment contributes 20 percent of global procedural volume.

The RBC apheresis segment is anticipated to reach USD 1.2 billion by 2030, accounting for approximately 22.4% of the total market, with a CAGR of 8.5% from 2023 to 2030.

Top 5 Major Dominant Countries in the RBC Segment

• United States: Projected to attain USD 350 million by 2030, representing 29.2% of the RBC market, growing at a CAGR of 8.1%.
• Germany: Expected to reach USD 180 million by 2030, capturing 15% market share, with a CAGR of 7.9%.
• China: Forecasted at USD 150 million by 2030, holding 12.5% share, expanding at a CAGR of 9.3%.
• Japan: Anticipated to achieve USD 120 million by 2030, comprising 10% of the market, with a CAGR of 8.7%.
• India: Estimated at USD 100 million by 2030, accounting for 8.3% share, growing at a CAGR of 9.8%.

Platelets Apheresis (plateletpheresis): Platelet apheresis supports patients in liver disease, myelofibrosis and trauma; platelet demand has risen 10 percent year‑on‑year in multiple blood centers. Plateletpheresis devices are used in over 3 000 donation centers in North America. Platelet-rich plasma collection is used in hundreds of medical facilities for regenerative medicine and orthopedic applications, accounting for 15 percent of total device usage globally.

The platelet apheresis segment is expected to reach USD 1.5 billion by 2030, constituting 28% of the market, with a CAGR of 9.5% from 2023 to 2030.

Top 5 Major Dominant Countries in the Platelet Segment

• United States: Projected at USD 450 million by 2030, representing 30% of the platelet market, with a CAGR of 9.2%.
• France: Expected to reach USD 200 million by 2030, capturing 13.3% share, growing at a CAGR of 8.9%.
• China: Forecasted at USD 180 million by 2030, holding 12% share, expanding at a CAGR of 10.1%.
• Japan: Anticipated to achieve USD 160 million by 2030, comprising 10.7% of the market, with a CAGR of 9.4%.
• Brazil: Estimated at USD 130 million by 2030, accounting for 8.7% share, growing at a CAGR of 9.6%.

Plasma Apheresis (plasmapheresis): Plasmapheresis stands at roughly 51.98 percent of procedure share in 2023, driven by treatment of leukemia, lymphoma, myeloma and lipid metabolism disorders. Global plasma donation infrastructure supports disposable kit consumption of 2 092.2 million USD in 2023. In the U.S. 184 720 hematologic malignancy diagnoses in 2023 created substantial demand for plasmapheresis across therapy units in tertiary centers.

The plasma apheresis segment is projected to reach USD 2.65 billion by 2030, making up 49.5% of the market, with a CAGR of 9.8% from 2023 to 2030.

Top 5 Major Dominant Countries in the Plasma Segment

• United States: Expected to attain USD 800 million by 2030, representing 30.2% of the plasma market, with a CAGR of 9.4%.
• Germany: Projected at USD 400 million by 2030, capturing 15.1% share, growing at a CAGR of 9.0%.
• China: Forecasted at USD 350 million by 2030, holding 13.2% share, expanding at a CAGR of 10.5%.
• Japan: Anticipated to achieve USD 300 million by 2030, comprising 11.3% of the market, with a CAGR of 9.7%.
• India: Estimated at USD 250 million by 2030, accounting for 9.4% share, growing at a CAGR of 10.2%.

BY APPLICATION

Centrifugation Apheresis Equipment: Centrifugal separation remains the predominant application segment, used in donor plasma, RBC, platelet, leukocyte collection. Centrifugation platforms captured the bulk of device revenues (majority share of 2 898.9 million USD market in 2023) and dominate installations in blood centers and hospitals globally. Centrifugation-based devices support 72 percent of product spend in disposable kits and devices units, and they account for 60 percent of installed base across regions.

Centrifugation-based equipment is projected to reach USD 3.2 billion by 2030, accounting for 59.8% of the market, with a CAGR of 8.9% from 2023 to 2030.

Top 5 Major Dominant Countries in the Centrifugation Application

• United States: Expected to attain USD 950 million by 2030, representing 29.7% of the centrifugation market, with a CAGR of 8.6%.
• Germany: Projected at USD 500 million by 2030, capturing 15.6% share, growing at a CAGR of 8.3%.
• China: Forecasted at USD 450 million by 2030, holding 14.1% share, expanding at a CAGR of 9.4%.
• Japan: Anticipated to achieve USD 400 million by 2030, comprising 12.5% of the market, with a CAGR of 8.8%.
• India: Estimated at USD 350 million by 2030, accounting for 10.9% share, growing at a CAGR of 9.1%.

Membrane Apheresis Equipment: Membrane separation systems are increasingly adopted in membrane filtration-based collections, particularly in Asia-Pacific and select European centers where membrane methods reduce hemolysis risk. Membrane apheresis application units rose by 15 percent in deployment in 2023. Membrane equipment accounted for 10–12 percent of global device shipments in 2023, with modest growth in specialized neurology and immunology applications.

Membrane-based equipment is anticipated to reach USD 2.15 billion by 2030, constituting 40.2% of the market, with a CAGR of 9.6% from 2023 to 2030.

Top 5 Major Dominant Countries in the Membrane Application

• United States: Projected at USD 650 million by 2030, representing 30.2% of the membrane market, with a CAGR of 9.2%.
• France: Expected to reach USD 300 million by 2030, capturing 14% share, growing at a CAGR of 8.9%.
• China: Forecasted at USD 280 million by 2030, holding 13% share, expanding at a CAGR of 10.1%.
• Japan: Anticipated to achieve USD 250 million by 2030, comprising 11.6% of the market, with a CAGR of 9.5%.
• Brazil: Estimated at USD 200 million by 2030, accounting for 9.3% share, growing at a CAGR of 9.8%.

Apheresis Equipment Market Regional Outlook

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

North America dominates the global Apheresis Equipment Market with an estimated market share of approximately 36% as of 2023. The United States accounts for the majority of this regional dominance, with a robust infrastructure of blood donation centers and healthcare institutions utilizing apheresis equipment regularly. The U.S. sees over 6.8 million blood donations annually, and nearly 29,000 units of red blood cells are transfused daily across hospitals, underlining the persistent and high demand for red cell and plasma apheresis. In 2023 alone, around 184,720 new cases of hematologic malignancies such as leukemia, lymphoma, and myeloma were reported in the U.S., directly increasing the demand for therapeutic apheresis procedures. Chronic kidney disease, affecting approximately 37 million adults in the U.S., and hemophilia A, occurring in roughly 1 out of every 5,000 male births, are major contributors to sustained apheresis usage. Neurological disorders such as multiple sclerosis and Guillain-Barré syndrome further increase demand, with neurology accounting for approximately 50.94% of the application share in the region. Furthermore, plasmapheresis procedures represent about 51.98% of the total procedural volume. With a mature healthcare system and high volume of specialized treatments, North America continues to lead in both device adoption and innovation within the Apheresis Equipment Market.

The North American Apheresis Equipment Market is projected to grow from USD 1.1 billion in 2024 to USD 2.26 billion by 2033, registering a CAGR of 8.34%.

North America - Major Dominant Countries in the Apheresis Equipment Market

• United States: Expected to reach USD 1.64 billion by 2030, representing a significant share of the North American market, with a CAGR of 8.6%.
• Canada: Projected at USD 300 million by 2030, capturing a notable market share, growing at a CAGR of 8.4%.
• Mexico: Forecasted at USD 200 million by 2030, holding a substantial share, expanding at a CAGR of 8.2%.
• Cuba: Anticipated to achieve USD 100 million by 2030, comprising a significant portion of the market, with a CAGR of 8.0%.
• Dominican Republic: Estimated at USD 90 million by 2030, accounting for a notable share, growing at a CAGR of 7.8%.

EUROPE

Europe represents the second-largest region in the global Apheresis Equipment Market, with a market share close to 30% as of 2023. Countries such as Germany, the United Kingdom, France, and Italy lead in terms of device installations and procedural volume. The region’s increasing prevalence of hematological and neurological diseases contributes significantly to apheresis demand. Multiple sclerosis, for instance, affects approximately 2.8 million people globally, with a large proportion residing in European countries. Plasma exchange and leukapheresis are frequently utilized in treatment protocols for autoimmune and hematological conditions. Europe also witnesses strong demand for plateletpheresis in treating patients with liver disease and myelofibrosis. Membrane apheresis techniques are gaining traction in Western Europe due to reduced hemolysis risk and patient-friendly design, accounting for nearly 10–12% of device use in the region. The region benefits from comprehensive reimbursement frameworks and national health services that support wider accessibility to advanced medical technologies, including apheresis equipment. European countries also prioritize safe blood component separation and storage practices, contributing to significant investment in disposable kit innovations and closed-loop systems. Additionally, a steady rise in voluntary blood donors and government-backed awareness campaigns has improved procedural frequency across donation centers, making Europe a critical player in shaping future market trends.

The European Apheresis Equipment Market is expected to grow from USD 1.0 billion in 2024 to USD 2.0 billion by 2033, registering a CAGR of 8.0%.

Europe - Major Dominant Countries in the Apheresis Equipment Market

• Germany: Projected at USD 600 million by 2030, representing a significant share of the European market, with a CAGR of 8.2%.
• France: Expected to reach USD 500 million by 2030, capturing a notable market share, growing at a CAGR of 8.0%.
• United Kingdom: Forecasted at USD 400 million by 2030, holding a substantial share, expanding at a CAGR of 7.8%.
• Italy: Anticipated to achieve USD 300 million by 2030, comprising a significant portion of the market, with a CAGR of 7.6%.
• Spain: Estimated at USD 200 million by 2030, accounting for a notable share, growing at a CAGR of 7.4%.

ASIA-PACIFIC

The Asia-Pacific region is rapidly emerging as a high-growth territory in the Apheresis Equipment Market, holding an approximate 28% share globally in 2023. Japan remains the leading country in the region, with a well-developed healthcare infrastructure and a rapidly aging population that demands apheresis-based treatments for autoimmune and hematologic conditions. China and India are also witnessing a notable increase in equipment deployment due to rising disease prevalence and government investments in healthcare infrastructure. Equipment installations in Japan, China, and India combined reached several hundred units by the end of 2023. Disposable kit usage has surged, with year-on-year growth of around 15%, supported by increasing awareness among healthcare professionals and patients. The growing incidence of blood disorders, chronic kidney diseases, and neurological conditions in densely populated countries continues to drive procedural volumes. Membrane apheresis technology, in particular, has gained significant ground in Asia-Pacific due to its cost-effectiveness and safety profile. Healthcare providers are also exploring the use of apheresis in regenerative medicine, contributing to its broader applications. National blood programs, especially in India and China, have improved donor recruitment, leading to higher volumes of platelet and plasma collections. Asia-Pacific presents substantial opportunities for new market entrants, training programs, and AI-integrated device platforms.

The Asian Apheresis Equipment Market is projected to grow from USD 800 million in 2024 to USD 1.8 billion by 2033, registering a CAGR of 9.0%.

Asia - Major Dominant Countries in the Apheresis Equipment Market

• China: Expected to reach USD 700 million by 2030, representing a significant share of the Asian market, with a CAGR of 9.6%.
• Japan: Anticipated to achieve USD 500 million by 2030, accounting for 27.8% of the regional share, growing at a CAGR of 8.7%.
• India: Projected to attain USD 450 million by 2030, holding 25% of Asia’s market, with a strong CAGR of 9.9%.
• South Korea: Estimated at USD 300 million by 2030, comprising 16.7% market share, expanding steadily at a CAGR of 8.8%.
• Australia: Expected to reach USD 250 million by 2030, contributing 13.9% to the regional total, with a CAGR of 8.5%.

MIDDLE EAST & AFRICA

The Middle East & Africa (MEA) region currently holds a smaller share in the global Apheresis Equipment Market, estimated at around 6–8% in 2023, but shows signs of steady growth. Countries like the United Arab Emirates, Saudi Arabia, and South Africa are gradually expanding their healthcare capabilities to include advanced therapeutic technologies like apheresis. Device installations in the region remain limited but are growing at a consistent rate of around 5% annually. The total number of blood donations in the region is significantly lower than in developed countries, often numbering in the hundreds of thousands annually. However, increased awareness and national health campaigns are contributing to improved donation volumes. Usage of apheresis equipment is mainly limited to tertiary care hospitals and specialized blood centers, with disposable kit spending remaining in the low tens of millions USD range. There is a growing need for treatment of hematologic and autoimmune disorders, and government initiatives to modernize healthcare are gradually improving the accessibility of such equipment. Membrane-based systems are gaining interest due to their compatibility with emerging health protocols. Though currently underserved, MEA holds potential for long-term growth in both donor and therapeutic apheresis applications, especially with infrastructure investment and workforce training programs.

The Middle East and Africa Apheresis Equipment Market is forecasted to expand from USD 500 million in 2024 to USD 1.1 billion by 2033, marking a CAGR of 8.5%.

Middle East and Africa - Major Dominant Countries in the Apheresis Equipment Market

• Saudi Arabia: Expected to reach USD 300 million by 2030, holding 27.2% of the regional market, with a CAGR of 8.8%.
• United Arab Emirates: Projected at USD 250 million by 2030, accounting for 22.7% share, growing at a CAGR of 8.6%.
• South Africa: Anticipated to achieve USD 200 million by 2030, capturing 18.2% share, expanding at a CAGR of 8.4%.
• Egypt: Forecasted at USD 180 million by 2030, making up 16.3% of the market, with a CAGR of 8.3%.
• Nigeria: Estimated at USD 150 million by 2030, representing 13.6% share, growing at a CAGR of 8.0%.

List of Top Apheresis Equipment Companies

• Haemonetics Corporation: Haemonetics is one of the top two leading companies in the Apheresis Equipment Market, with a strong global presence in over 50 countries. The company operates across donor and therapeutic apheresis segments and is a leading supplier of automated blood collection systems. In FY 2024, Haemonetics supported over 160 million USD in strategic acquisitions, including Attune Medical, to enhance its thermal management portfolio. The company’s platforms are used in more than 3,000 blood collection centers worldwide. Haemonetics holds a dominant share in the U.S. plasma collection market and leads with high-volume installations across hospitals and donor facilities.
• Fresenius Medical Care: Fresenius Medical Care ranks among the top two companies in the Apheresis Equipment Market, with global leadership in dialysis and therapeutic apheresis solutions. The company operates 4,171 dialysis clinics worldwide, serving over 345,425 patients. In the U.S. alone, Fresenius controls approximately 38% of the dialysis market. It manufactures and distributes apheresis systems through its extensive network, supporting hospitals and blood centers across North America, Europe, and Asia-Pacific. The company’s apheresis platforms are widely used for plasma exchange, leukapheresis, and photopheresis therapies.
• Therakos: Therakos is recognized for its specialization in extracorporeal photopheresis (ECP) systems. Its CELLEX and UVAR XTS systems are extensively used for the treatment of cutaneous T-cell lymphoma and graft-versus-host disease in transplant recipients. The company has a notable footprint in North America and Europe and focuses on advanced therapy segments within the apheresis space.
• Asahi Kasei Medical Co., Ltd.: Asahi Kasei Medical is a major manufacturer of membrane separation systems and therapeutic apheresis devices. The company acquired Bionova Scientific in June 2022 to strengthen its biopharmaceutical processing capabilities. Its apheresis product lines are used in Asia-Pacific and global markets, with strong integration in hospitals for plasma filtration and endotoxin removal applications.
• Kawasumi Laboratories Inc.: Kawasumi Laboratories produces apheresis kits and related disposables used primarily in blood banks and transfusion centers across Japan and selected global markets. The company emphasizes safety and precision in donor plasma collection and continues to innovate in consumable medical technology.
• Braun Melsungen AG: B. Braun is a prominent global player providing a wide range of healthcare technologies, including apheresis solutions. The company’s devices are used in critical care, plasma collection, and therapeutic interventions. It supports installations in more than 60 countries, with a growing presence in Europe and Latin America.
• Macopharma: Macopharma develops and manufactures blood collection and apheresis disposables, including platelet storage bags and plasma filters. It operates in over 70 countries, offering tailored solutions to blood centers, hospitals, and biopharma industries, with a focus on membrane-based separation.
• NIKKISO Co., Ltd.: NIKKISO offers blood purification systems, including apheresis machines for therapeutic applications such as plasma exchange and leukapheresis. It has a strong market presence in Japan and Southeast Asia, with gradual expansion into Europe and the Middle East.
• Terumo BCT, Inc.: Terumo BCT is a global innovator in apheresis technology, known for its Spectra Optia system, which is used in more than 125 countries. The company launched a global cell therapy training program in May 2023, training hundreds of cell manufacturers in advanced apheresis techniques. Terumo is a significant player in both donor and therapeutic markets and continues to expand its AI-enabled and bedside photopheresis offerings.
• Medica S.p.A.: Medica S.p.A. manufactures medical devices and filters for blood purification and plasma separation. Based in Italy, it exports products to over 60 countries. The company is expanding into the therapeutic apheresis sector with a focus on innovation in filtration-based technologies.

Investment Analysis and Opportunities

Investment in the Apheresis Equipment Market Report context reveals opportunity in capital deployment across device manufacturers, disposable kit production and training infrastructure. The U.S. equipment market reached 917.9 million USD in 2023; projection for 2024 shows 1.01 billion USD market size, and strategic expansion in Asia-Pacific supports volume growth of several hundred million USD by 2025. Companies acquiring complementary businesses such as Haemonetics acquiring Attune Medical for 160 million USD demonstrate inorganic investment strategies. AI integration offers efficiency improvements (20 percent reduction in manual logging time) that enhance throughput in high-volume centers. Blood donation volumes in U.S. (6.8 million units annually) and chronic disease burden (e.g. 37 million adult renal patients, 2.8 million MS cases) underpin demand forecasts. Investments in training programs Terumo BCT’s program launched May 2023 support market expansion in cell therapy. Regions like Middle East & Africa show incremental device installations (5 percent annual growth), but capital expansion remains limited. Investors can focus on emerging economies to introduce membrane-based systems (currently 10–12 percent share) where procedural safety and cost-sensitivity offer entry points. These figures frame clear investment potential within the Apheresis Equipment Market Opportunities for B2B stakeholders.

New Product Development

Innovation in Apheresis Equipment Market New product development centers on AI-enabled separation systems, closed‑loop photopheresis platforms, enhanced disposable kits, and integrated cell collection training tools. In 2024, AI algorithms were embedded across thousands of procedures, improving accuracy and reducing manual error margins by 20 percent. Disposable kit technologies generated 2 092.2 million USD in 2023 product spend; innovations in kit materials reduced assay downtime by 10 percent. Terumo BCT introduced direct bedside extracorporeal photopheresis (ECP) in July 2021, enabling mononuclear cell collection protocols that expanded device capability. Asahi Kasei Medical leveraged its Bionova acquisition (June 2022) to develop consumables used in biopharma process design, driving unit shipment growth in hundreds of systems. Centrifugation devices received upgrades to faster spin cycles, reducing separation time by 15 percent per session. Membrane separation platforms grew device installations by 15 percent in 2023, thanks to filters with lower hemolysis risk. Training programs, such as Terumo’s May 2023 cell collection initiative, equip hundreds of users annually on next‑generation collection processes. These developments underscore robust New Product Development and Market Insights for companies targeting Apheresis Equipment Industry Report needs.

Five Recent Developments (2023–2025)

• In 2023, a manufacturer introduced advanced apheresis equipment capable of processing blood flow rates exceeding 120 ml per minute, improving plasma collection efficiency by 25% across procedures performed on more than 1 million donors annually.
• In 2024, a company launched automated apheresis systems with separation accuracy above 98%, enabling collection of specific blood components such as platelets and plasma within 60 to 90 minutes per procedure.
• In early 2025, a developer introduced portable apheresis equipment weighing below 25 kg, supporting deployment across more than 500 mobile blood collection units serving populations exceeding 10 million.
• In 2023, a production facility expanded manufacturing capacity to produce over 20,000 apheresis units annually, supporting demand across more than 70 countries and over 5,000 healthcare facilities.
• In 2024, a manufacturer developed next-generation apheresis devices with integrated monitoring systems capable of tracking over 100 parameters per procedure, improving safety and reducing adverse events by up to 15% across clinical settings.

Report Coverage of Apheresis Equipment Market

The Apheresis Equipment Market Report provides comprehensive coverage of device types, technologies, and application areas across hospitals, blood banks, and research laboratories. This Apheresis Equipment Market Analysis includes equipment capable of processing blood volumes exceeding 5 liters per session and separating components such as plasma, platelets, and leukocytes with efficiency levels above 95%. The report evaluates Apheresis Equipment Market Size across applications, where plasma collection accounts for over 60% of usage due to increasing demand for plasma-derived therapies used in treatment of more than 200 diseases globally. Apheresis Equipment Market Research Report insights also include segmentation by product type, with automated apheresis systems accounting for over 70% of installations due to their ability to handle procedures exceeding 10,000 cycles per unit.

The Apheresis Equipment Industry Report further examines performance metrics such as processing times ranging from 60 minutes to 120 minutes per procedure, separation accuracy above 98%, and device lifespan exceeding 8,000 to 10,000 operational cycles. Apheresis Equipment Market Outlook highlights regional adoption trends, where developed regions account for more than 65% of installations due to advanced healthcare systems supporting blood collection volumes exceeding 10 million donations annually. Additionally, the report analyzes integration with digital monitoring technologies capable of tracking over 100 parameters per procedure. Apheresis Equipment Market Opportunities are explored through increasing demand for therapeutic apheresis procedures performed on more than 1 million patients annually, providing detailed insights into market expansion and technological advancements.

Apheresis Equipment Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 2725.63 Million in 2026
Market Size Value By	USD 7440.24 Million by 2035
Growth Rate	CAGR of 11.8% from 2026-2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Centrifugation Apheresis Equipment Membrane Apheresis Equipment By Application : RBC Platelets Plasma
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample